Literature DB >> 30659079

Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101).

Kosuke Takahashi1,2, Masashi Kondo3, Masahiko Ando4, Akira Shiraki5, Harunori Nakashima5, Hisashi Wakayama6, Kensuke Kataoka7, Masashi Yamamoto8, Yasuteru Sugino9, Mitsunori Nishikawa10, Kazuyoshi Imaizumi3, Eiji Kojima11, Atsushi Sumida12, Yoshihiro Takeyama13, Hiroshi Saito14, Yoshinori Hasegawa2.   

Abstract

BACKGROUND: Although the efficacy of parenteral morphine for alleviating dyspnea has been previously demonstrated in several studies, little is known regarding the efficacy of oral morphine for dyspnea among patients with cancer, including its response rate and predictive factors of effectiveness. Therefore, the aim of this study was to clarify the effectiveness of oral morphine on dyspnea in patients with cancer and elucidate the predictive factors of its effectiveness. SUBJECTS, MATERIALS, AND METHODS: In this multicenter prospective observational study, we investigated the change in dyspnea intensity in patients with cancer before and after the administration of oral morphine by using a visual analog scale (VAS). We also administered a self-assessment questionnaire to determine whether the patients believed oral morphine was effective.
RESULTS: Eighty patients were enrolled in the study, and 71 of these patients were eligible. The least square mean of the VAS scores for dyspnea intensity was 53.5 at baseline, which decreased significantly to 44.7, 40.8, and 35.0 at 30, 60, and 120 minutes after morphine administration, respectively. Fifty-four patients (76.1%) reported that oral morphine was effective on the self-assessment questionnaire. Among the background factors, a high score for "sense of discomfort" on the Cancer Dyspnea Scale (CDS) and a smoking history of fewer pack-years were associated with greater effectiveness.
CONCLUSION: Oral morphine was effective and feasible for treating cancer-related dyspnea. A higher score for "sense of discomfort" on the CDS and a smaller cumulative amount of smoking may be predictive factors of the effectiveness of oral morphine. IMPLICATIONS FOR PRACTICE: This study demonstrated that oral morphine was effective in alleviating cancer-related dyspnea due to multiple factors including primary lung lesions, airway narrowing, and pleural effusion. Approximately 76% of patients reported that oral morphine was effective. A higher score for "sense of discomfort" on the Cancer Dyspnea Scale and a lower cumulative amount of smoking may be predictive factors for the effectiveness of oral morphine. Interestingly, respiratory rates in patients who reported the morphine to be effective decreased significantly after oral morphine administration, unlike the respiratory rates in "morphine-ineffective" patients. © AlphaMed Press 2019.

Entities:  

Keywords:  Cancer; Clinically meaningful change; Dyspnea; Morphine; Predictive factor

Mesh:

Substances:

Year:  2019        PMID: 30659079      PMCID: PMC6656455          DOI: 10.1634/theoncologist.2018-0468

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  34 in total

1.  Postoperative opiate analgesia requirements of smokers and nonsmokers.

Authors:  Freddy M Creekmore; Ralph A Lugo; Kevin J Weiland
Journal:  Ann Pharmacother       Date:  2004-04-27       Impact factor: 3.154

2.  The development of cross-tolerance between morphine and nicotine in mice.

Authors:  M R Zarrindast; M R Khoshayand; B Shafaghi
Journal:  Eur Neuropsychopharmacol       Date:  1999-03       Impact factor: 4.600

Review 3.  A systematic review of the use of opioids in the management of dyspnoea.

Authors:  A-L Jennings; A N Davies; J P T Higgins; J S R Gibbs; K E Broadley
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

4.  The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial.

Authors:  C Mazzocato; T Buclin; C H Rapin
Journal:  Ann Oncol       Date:  1999-12       Impact factor: 32.976

5.  Clinically meaningful changes in quantitative measures of asthma severity.

Authors:  D J Karras; M E Sammon; C A Terregino; B L Lopez; S K Griswold; G K Arnold
Journal:  Acad Emerg Med       Date:  2000-04       Impact factor: 3.451

Review 6.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 7.  Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.

Authors:  Scott C Armstrong; Kelly L Cozza
Journal:  Psychosomatics       Date:  2003 Mar-Apr       Impact factor: 2.386

Review 8.  Clinical management of dyspnoea.

Authors:  Jay R Thomas; Charles F von Gunten
Journal:  Lancet Oncol       Date:  2002-04       Impact factor: 41.316

9.  Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer.

Authors:  Keiko Tanaka; Tatsuo Akechi; Toru Okuyama; Yutaka Nishiwaki; Yosuke Uchitomi
Journal:  J Pain Symptom Manage       Date:  2002-06       Impact factor: 3.612

10.  Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale.

Authors:  K Tanaka; T Akechi; T Okuyama; Y Nishiwaki; Y Uchitomi
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  2 in total

1.  Physician-Perceived Predictive Factors for the Effectiveness of Drugs for Treating Cancer Dyspnea: Results of a Nationwide Survey of Japanese Palliative Care Physicians.

Authors:  Yoshinobu Matsuda; Ryo Matsunuma; Kozue Suzuki; Masanori Mori; Hiroaki Watanabe; Takashi Yamaguchi
Journal:  Palliat Med Rep       Date:  2020-06-30

2.  Experience of symptom control, anxiety and associating factors in a palliative care unit evaluated with Support Team Assessment Schedule Japanese version.

Authors:  Tetsuya Ito; Emi Tomizawa; Yuki Yano; Kiyozumi Takei; Naoko Takahashi; Fumio Shaku
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.